Natera is a global leader in genetic testing and diagnostics, providing advanced solutions that help clinicians and patients make informed healthcare decisions. Founded in 2004, the company specializes in non-invasive prenatal testing (NIPT), hereditary cancer screening, organ transplant monitoring, and other genetic assays that leverage innovative cell-free DNA analysis.

Headquartered in San Carlos, California, Natera has established a strong presence in the healthcare and biotechnology sectors, with laboratories and offices across North America, Europe, and other regions. The company’s mission is to improve health outcomes by delivering accurate, timely, and actionable genetic information.

Natera’s core technology revolves around its proprietary Signatera, Panorama, and Horizon platforms, which enable personalized and highly sensitive detection of genetic conditions. These tests are used by clinicians to tailor treatments, monitor disease progression, and screen for genetic risks, thereby advancing the field of precision medicine.

Through continuous innovation and a commitment to scientific excellence, Natera aims to transform the standard of care in reproductive health, cancer management, and organ health. Its focus on research and development ensures that it remains at the forefront of genetic testing advancements, fostering better patient outcomes worldwide.